TREMFYA PsA data reinforces backfill hypothesis but doesn't resolve key risks
Read source articleWhat happened
Johnson & Johnson announced that TREMFYA demonstrated statistically significant improvement in disease activity and more than two times greater reduction in MRI-assessed inflammation versus placebo at Week 24 in a Phase 4 study of biologic-naïve adults with active psoriatic arthritis and axial involvement. This is the first-ever PsA study using objective MRI assessments to confirm and measure axial inflammation, positioning TREMFYA as the only advanced therapy with such confirmed benefit. The DeepValue master report assigns JNJ a WAIT rating at $228.40, citing near-term headwinds including STELARA biosimilar erosion (sales down 59.7% YoY in Q1 FY2026) and unbounded talc litigation risk, while highlighting TREMFYA as a key backfill driver if it scales rapidly. The new data supports TREMFYA's differentiation in immunology, but it addresses only a subset of psoriatic arthritis and does not alter the overarching concerns about PBM-driven STELARA decline or legal liabilities. Moreover, the announcement is a company-sponsored press release, warranting independent validation of the claimed efficacy and market impact.
Implication
The positive TREMFYA PsA results add to evidence of efficacy in a specific subpopulation, potentially supporting market share gains in psoriatic arthritis without altering near-term financial headwinds. The DeepValue report already factors TREMFYA as a growth driver, but the immediate revenue impact from this data is likely limited compared to the ongoing ulcerative colitis launch. JNJ's valuation remains dominated by STELARA erosion and talc litigation, neither of which is addressed by this news. Investors should monitor subsequent regulatory filings, real-world adoption, and payer contracts for TREMFYA to gauge whether it can offset declines elsewhere. Overall, the thesis of waiting for Q2-Q3 FY2026 proof of immunology stabilization is unchanged, and this data alone does not warrant a rating upgrade.
Thesis delta
The core thesis remains WAIT: JNJ faces discrete near-term catalysts (CVS formulary shift on July 1, 2026; talc evidentiary rulings) that outrank the incremental positive from TREMFYA's PsA data. This news reinforces the potential upside from immunology backfill but does not resolve the timing or magnitude of STELARA erosion or litigation risk. Therefore, the thesis is unchanged; the data is consistent with the existing bull scenario but does not tip the balance.
Confidence
Moderate-High